Brewer Hannah R, Hirst Yasemin, Sundar Sudha, Chadeau-Hyam Marc, Flanagan James M
Surgery and Cancer, Imperial College London, London, UK.
Behavioural Science and Health, University College London, London, UK.
BMJ Open. 2020 Sep 8;10(9):e037459. doi: 10.1136/bmjopen-2020-037459.
Ovarian cancer is the eighth most common cancer in women worldwide, and about 1 in 5 women with ovarian cancer do not receive treatment, because they are too unwell by the time they are diagnosed. Symptoms of ovarian cancer are non-specific or can be associated with other common conditions, and women experiencing these symptoms have been shown to self-manage them using over-the-counter medication. Results from a recent proof-of-concept study suggest there may be an increase in the purchases of painkillers and indigestion medication 10-12 months before ovarian cancer diagnosis. We propose a case-control study, as part of a larger project called the Cancer Loyalty Card Study (CLOCS), to investigate whether a significant change in medication purchases could be an indication for early signs of ovarian cancer, using data already collected through store loyalty cards.
Using a retrospective case-control design, we aim to recruit 500 women diagnosed with ovarian cancer (cases) and 500 women without ovarian cancer (controls) in the UK who hold a loyalty card with at least one participating high street retailer. We will use pre-existing loyalty card data to compare past purchase patterns of cases with those of controls. In order to assess ovarian cancer risk in participants and their purchase patterns, we will collect information from participants on ovarian cancer risk factors and clinical data including symptoms experienced before diagnosis from recruited women with ovarian cancer.
CLOCS was reviewed and approved by the North West-Greater Manchester South Research Ethics Committee (19/NW/0427). Study outcomes will be disseminated through academic publications, the study website, social media and a report to the research sites that support the study once results are published.
ISRCTN 14897082, CPMS 43323, NCT03994653.
卵巢癌是全球女性中第八大常见癌症,约五分之一的卵巢癌女性患者未接受治疗,因为她们在确诊时身体状况太差。卵巢癌的症状不具特异性,或与其他常见病症相关,有这些症状的女性已被证明会使用非处方药自行处理。最近一项概念验证研究的结果表明,在卵巢癌确诊前10 - 12个月,止痛药和消化不良药物的购买量可能会增加。我们提议开展一项病例对照研究,作为名为癌症忠诚卡研究(CLOCS)的更大项目的一部分,利用已通过商店忠诚卡收集的数据,调查药物购买量的显著变化是否可能是卵巢癌早期迹象的一个指标。
采用回顾性病例对照设计,我们旨在招募500名在英国被诊断为卵巢癌的女性(病例组)和500名未患卵巢癌的女性(对照组),她们持有至少一家参与项目的商业街零售商的忠诚卡。我们将使用现有的忠诚卡数据,比较病例组和对照组过去的购买模式。为了评估参与者的卵巢癌风险及其购买模式,我们将从参与者那里收集有关卵巢癌风险因素的信息以及临床数据,包括从招募的卵巢癌女性患者中获取她们在确诊前经历的症状。
CLOCS已由西北 - 大曼彻斯特南部研究伦理委员会审查并批准(19/NW/0427)。研究结果将通过学术出版物、研究网站、社交媒体进行传播,一旦结果发表,还将向支持该研究的研究地点提交一份报告。
ISRCTN 14897082,CPMS 43323,NCT03994653。